Please cancel claims 19-25, amend claims 16 and 34, and add new claims 37-42, as follows:

Claims 1-15 (Cancelled).

Claim 16 (Currently Amended) A composition comprising:

a phospholipid having an n-3 polyunsaturated fatty acid constituent selected from the group

consisting of docosahexaenoic acid, docosapentaenoic acid and eicosapentaenoic acid; and

 α -linolenic acid, and/or an oil comprising α linolenic acid

wherein a weight ratio of the α -linolenic acid to the phospholipid is 0.1-20:1.

Claim 17 (Previously Presented) The composition according to claim 16, wherein the

phospholipid is one or more phospholipids selected from the group consisting of phosphatidyl

choline, phosphatidyl serine, phosphatidyl ethanolamine, phosphatidyl inositol, phosphatidic acid

and phosphatidyl cardiolipin.

Claim 18 (Previously Presented) The composition according to claim 16, wherein the

phospholipid is selected from the group consisting of a phosphatidyl serine having

docosahexaenoic acid as the n-3 polyunsaturated fatty acid constituent thereof, a phosphatidyl

serine having eicosapentaenoic acid as the n-3 polyunsaturated fatty acid constituent thereof, a

phosphatidyl choline having docosahexaenoic acid as the n-3 polyunsaturated fatty acid constituent

thereof, a phosphatidyl choline having eicosapentaenoic acid as the n-3 polyunsaturated fatty acid

constituent thereof, and combinations thereof.

Claims 19-25 (Cancelled).

2

Claim 26 (Previously Presented) The composition according to claim 16, wherein the

composition further comprises one or more compounds selected from the group consisting of

ginseng, Panax notoginseng, Siberian ginseng, arginine, Ginkgo biloba, soybean, carnitine,

bilberry, blueberry, raspberry, rutin, cassis, citric acid, sesame, sprouted sesame, rutin, garlic,

onion, fermented soybeans, Echinacea, black cohosh, vitamin C, vitamin E, catechin, astaxanthin,

sesamin and polyphenols.

Claim 27 (Previously Presented) The composition according to claim 16, wherein the

composition further comprises one or more compounds selected from the group consisting of

ginseng, Panax notoginseng, Siberian ginseng, arginine, Ginkgo biloba, bilberry, rutin and vitamin

E.

Claim 28 (Previously Presented) The composition according to claim 16, wherein the

composition further comprises one or more additives selected from the group consisting of a

pharmaceutically acceptable carrier, an excipient, a binder, a disintegrant, a stabilizer, a dispersant,

a coloring agent, a taste corrigent, a plant oil and a surfactant.

Claim 29 (Previously Presented) A food or beverage comprising the composition according

to claim 16.

Claim 30 (Previously Presented) The food or beverage according to claim 29, wherein the

food or beverage is in the form of a solid, a gel or a liquid.

3

Claim 31 (Previously Presented) The food or beverage according to claim 29, wherein the food or beverage is attached with a label indicating that the food or beverage improves central nervous function, visual acuity or circulatory function.

Claim 32 (Previously Presented) A medicament comprising the composition according to claim 16 and a pharmaceutically acceptable carrier.

Claim 33 (Previously Presented) The medicament according to claim 32, wherein the medicament is in the form of a powder, a granule, a capsule, a tablet, a pill or a troche.

Claim 34 (Withdrawn-Currently Amended) A process for preparing the composition according to claim 16, wherein said process comprises dissolving the phospholipid[[,]] and the α -linolenic acid and/or the oil comprising α linolenic acid under stirring.

Claim 35 (Withdrawn) A method for improving central nervous function comprising administering the composition according to claim 16.

Claim 36 (Withdrawn) A method for improving circulatory function comprising administering the composition according to claim 16.

Claim 37 (New) The composition according to claim 16, wherein the weight ratio of the α -linolenic acid to the phospholipid is 0.25-10:1.

Claim 38 (New) The composition according to claim 16, wherein the weight ratio of the α -linolenic acid to the phospholipid is 0.5-4:1.

Application No. 10/582,940

Attorney Docket No. 292106US0PCT

Response to Official Action dated January 26, 2009

Claim 39 (New) The composition according to claim 16, wherein the weight ratio of the α -

linolenic acid to the phospholipid is 0.75-2:1.

Claim 40 (New) The composition according to claim 16, wherein the weight ratio of the α-

linolenic acid to the phospholipid is 2-20:1.

Claim 41 (New) The composition according to claim 16, wherein the weight ratio of the α -

linolenic acid to the phospholipid is 4-20:1.

Claim 42 (New) The composition according to claim 16, wherein the weight ratio of the α -

linolenic acid to the phospholipid is 10-20:1.

5